Sign in
WithdrawnNo phase

Study of MSC-Exo on the Therapy for Intensively Ill Children

Key facts

Who runs it
Children's Hospital of Fudan University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Sept 2022
Ended
31 Dec 2024
Type of study
Observational, 2 groups
Record updated
15 June 2022
Why it stopped
Lacking of funding

Who can take part

Age
29 days to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • children hospitalized in PICU of Children's Hospital of Fudan University

Who cannot take part

  • discharge within 48 hours
  • patients without informed consent
  • incomplete clinical and demographic data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

At present, a number of projects related to MSCs have been approved for graft-versus-host disease, myocardial infarction, Crohn's disease and other diseases, indicating a strong therapeutic potential of MSCs. However, the efficacy of MSC-Exo for severely infected children is not fully evaluated. In our study, patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. This study will evaluate the application and therapeutic effect of MSC-Exo in severely infected children, and determine the Optimal dosage and infusion.

The 2 groups in the trial

  • trial group

    Mesenchymal Stem Cell-Derived Exosomes

  • control group

    conventional treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study of Exosomes Derived From Mesenchymal Stem Cells on the Therapy for Children With Severe Infection
Record updated
15 June 2022